Cabo Beltran, Olga Rodriguez <br/><br/>
MVA E2 therapeutic vaccine for marked reduction in likelihood of recurrence of respiratory papillomatosis.  [electronic resource] 

 -  Head & neck  03 2019 
 - 657-665 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1097-0347 
<br/><br/><label>Standard No.: </label>10.1002/hed.25477  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adolescent<br/>Adult<br/>Aged<br/>Child<br/>Child, Preschool<br/>Female<br/>Follow-Up Studies<br/>Humans<br/>Laryngoscopy<br/>Male<br/>Middle Aged<br/>Papillomavirus Infections--pathology<br/>Respiratory Tract Infections--pathology<br/>Survival Analysis<br/>Treatment Outcome<br/>Vaccines, DNA<br/>Viral Vaccines<br/>Young Adult